Absci vs Insilico Medicine (2026)
Absci and Insilico Medicine are both listed generative AI drug developers with clinical programs from their own platforms, and CB Insights lists Insilico among Absci's competitors. They work on different molecules and sell in different ways. Absci designs antibodies with Origin-1 and its own laboratory, keeps its pipeline focused on prolactin receptor and cytokine biology, and partners programs rather than selling software; ABS-201 is in a Phase 1/2a trial. Insilico licenses its Pharma.AI software, including PandaOmics for target discovery, Chemistry42 for small molecule design and inClinico for trial outcome prediction, and runs more than 40 programs of its own. Rentosertib, a TNIK inhibitor for idiopathic pulmonary fibrosis whose target and molecule came from the platform, entered Phase III in September 2026, when the trial dosed its first patient. Absci suits a partner seeking antibodies; Insilico suits one that wants small molecule discovery software or a licensable small molecule program.
- Antibody design, from de novo binders to lead optimization.
- A wet lab that tests every design before it advances.
- A focused pipeline built around the prolactin receptor.
- Partnerships in place of software licenses, so no platform access is needed.
- Licensable software for target discovery, chemistry and trial prediction.
- A platform designed small molecule in Phase III.
- Thirteen programs cleared for IND since 2021.
- An ISO 27001 certified information security system for client work.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Absci and Insilico Medicine are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Absci | Insilico Medicine |
|---|---|---|
| Primary category | Drug Discovery AI | Drug Discovery AI |
| Founded | 2011 | 2014 |
| Headquarters | Vancouver, Washington | Cambridge, Massachusetts |
| Website | absci.com | insilico.com |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached.
Absci is an antibody company built on generative design: Origin-1 and lead optimization models propose candidates, and its own laboratory tests them in cycles of about six weeks. ABS-201, its furthest advanced program, is in an early stage clinical trial for pattern hair loss.
Source: AI Health Index, October 2026
Insilico Medicine sells the Pharma.AI suite for target discovery, small molecule design and trial outcome prediction, and develops its own medicines, led by rentosertib in Phase III for idiopathic pulmonary fibrosis.
Source: AI Health Index, October 2026
Questions buyers ask
Which molecules does each design?
Absci designs antibodies. Insilico's Chemistry42 generates small molecules, and the suite also includes a Generative Biologics module. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 12, 2026. No vendor pays for placement.
Can a customer license the software?
Insilico licenses PandaOmics, Chemistry42 and inClinico to research organizations and offers a box for local deployment. Absci sells no software and works through drug creation partnerships. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 12, 2026. No vendor pays for placement.
How far has each platform's lead program gone?
Rentosertib, from Insilico's platform, entered a Phase III trial in July 2026. Absci's ABS-201 is in Phase 1/2a, with proof of concept data due from late 2026. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 12, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
Insilico Medicine is listed in Hong Kong and Absci on Nasdaq. Insilico develops its own medicines in some of the areas where it licenses software.